Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Infectious Diseases›Condition·Updated Jun 27, 2026·v1

Clostridioides difficile Infection

Clostridioides difficile infection is a toxin-mediated diarrheal illness triggered by antibiotic-induced dysbiosis. Diagnosis requires a two-step algorithm (GDH + toxin EIA, NAAT as tiebreaker) to avoid overdiagnosis of colonization. Fidaxomicin 200 mg PO BID × 10 days is first-line for all initial episodes due to lower recurrence rates. Vancomycin is an acceptable alternative. Metronidazole is reserved for when neither is available. Recurrence occurs in 20-30% after a first episode and escalates with each recurrence; management includes fidaxomicin, bezlotoxumab, and fecal microbiota transplantation for multiple recurrences. Fulminant disease requires ICU care, combination therapy, and early surgical consultation. Prevention centers on antibiotic stewardship, PPI minimization, contact precautions, and soap-and-water hand hygiene.

High Evidence254 references·7,667 words·31 min read·v1
Clostridioides difficileCDIpseudomembranous colitisantibiotic-associated diarrheafidaxomicinvancomycinbezlotoxumabfecal microbiota transplantationhealthcare-associated infectioninfectious diseases

Quick Reference

RxDrug of choiceFidaxomicin 200 mg PO twice daily × 10 days (for all initial episodes, non-severe and severe; reduces recurrence by 40-50% vs vancomycin)
AltAlternativesVancomycin 125 mg PO QID × 10 days (when fidaxomicin unavailable); Metronidazole 500 mg PO TID × 10 days (only when fidaxomicin and vancomycin inaccessible; inferior efficacy)
⊘AvoidMetronidazole as first-line therapy (inferior sustained cure); Antimotility agents as monotherapy (risk of toxic megacolon); Non-dihydropyridine CCBs (not relevant; avoid unnecessary PPIs)
DxTest of choiceTwo-step algorithm: GDH EIA screening → if positive, toxin A/B EIA; if discordant, NAAT as tiebreaker. Do not use NAAT alone (cannot distinguish infection from colonization).
ScKey scoreIDSA/SHEA severity: severe = WBC >15,000 cells/μL or creatinine ≥1.5 mg/dL. Fulminant = hypotension, shock, ileus, megacolon. ATLAS score (Age, Temperature, Leukocytosis, Albumin, Systemic antibiotics) adds prognostic granularity.
→When to referFulminant CDI (urgent surgical consultation for possible colectomy or diverting loop ileostomy); Multiply recurrent CDI (≥3 episodes) for FMT; Cases unresponsive to therapy after 5-7 days.
Fidaxomicin 200 mg PO BID × 10 days is first-line for all initial CDI episodes; vancomycin is an acceptable alternative. Avoid metronidazole. Recurrence is the main long-term threat, managed with fidaxomicin, bezlotoxumab, or FMT. Antibiotic stewardship and soap-and-water hand hygiene are key prevention strategies.
Clostridioides difficile infection (CDI) is a toxin-mediated diarrheal illness of the colon, almost always triggered by antibiotic-induced disruption of the gut microbiome. CDI is the most common healthcare-associated infection in US hospitals, causing an estimated 500,000 infections and 15,000-30,000 deaths annually. The core management strategy begins with prompt diagnosis using a two-step algorithm (GDH + toxin EIA, with NAAT as tiebreaker), immediate initiation of fidaxomicin or vancomycin based on severity, and avoidance of metronidazole except in rare circumstances. Recurrence, the dominant long-term complication, affects 20-30% of patients after a first episode and can be mitigated by fidaxomicin, bezlotoxumab, or fecal microbiota transplantation.

Overview and Recommendations

Background

  • •Clostridioides difficile is a spore-forming, anaerobic, Gram-positive bacillus that produces two exotoxins, toxin A (TcdA) and toxin B (TcdB), which inactivate Rho-family GTPases, disrupting colonic epithelial tight junctions and triggering neutrophil infiltration, fluid secretion, and pseudomembrane formation. Hypervirulent strains, particularly ribotype 027 (BI/NAP1/027), produce higher toxin levels and carry binary toxin (CDT), contributing to epidemic spread and worse outcomes; in recent surveillance, ribotype 106 has replaced 027 as the dominant strain in some regions.
  • •CDI is the most common healthcare-associated infection in US hospitals, with an estimated 365,200 cases in 2017 (down from 462,100 in 2011, driven by a 24% reduction in healthcare-associated infections). Incidence peaks in adults ≥65 years, with rates 5-10 times higher than younger adults. Community-associated CDI remains stable at ~50 per 100,000.
  • •The essential precursor is antibiotic-induced dysbiosis. Broad-spectrum antibiotics deplete the gut microbiota, reducing colonization resistance and altering bile acid composition, primary bile acids (e.g., taurocholate) promote spore germination, while secondary bile acids (e.g., deoxycholate) inhibit vegetative growth. The loss of secondary bile acid production by commensal Clostridia is a key mechanism driving recurrence.
  • •CDI is classified along three axes: acquisition setting (healthcare-associated vs. community-associated), episode number (primary vs. recurrent, defined as recurrence within 8 weeks of a prior treated episode), and clinical severity (non-severe, severe, fulminant). Each axis carries distinct therapeutic and infection-control implications. Up to 30% of patients experience at least one recurrence.
  • •Host immune response determines clinical outcome. Patients with robust antitoxin antibody responses are less likely to develop recurrent disease. Conversely, immunosuppression (e.g., corticosteroids) does not increase CDI risk but may blunt the inflammatory response. Stool IL-1β and fecal IgA levels differentiate CDI from asymptomatic carriage and non-CDI diarrhea.
  • •The four pillars of CDI management, antibiotic stewardship, appropriate antimicrobial therapy (fidaxomicin over vancomycin for first episodes), microbiome restoration (bezlotoxumab, FMT for recurrences), and infection control (contact precautions, sporicidal cleaning), have replaced the legacy vancomycin-metronidazole paradigm, integrated following MODIFY I/II (2017), the IDSA/SHEA 2021 focused update, and subsequent high-quality RCTs demonstrating fidaxomicin's superiority in reducing recurrence.

Evaluation

  • •Suspect CDI in any patient with acute-onset, watery diarrhea (≥3 unformed stools in 24 hours) and recent antibiotic exposure (within the prior 8 weeks), especially in hospitalized patients, older adults, or those on PPIs. The classic triad is watery diarrhea, abdominal pain, and a history of antibiotic use.
  • •Ask about the timing of symptom onset relative to antibiotics (typically 5-10 days after initiation), stool frequency and character, presence of fever, tenesmus, or bloody stools (the latter may suggest IBD flare). Document any prior CDI episodes, recent hospitalizations, and use of PPIs or chemotherapeutic agents.
  • •Examine for abdominal tenderness (especially lower quadrants), hyperactive or diminished bowel sounds, signs of dehydration (dry mucous membranes, tachycardia, orthostatic hypotension), and fever >38.5°C. In fulminant disease, assess for abdominal rigidity, rebound tenderness, or a silent abdomen suggesting peritonitis or toxic megacolon.
  • •Order stool testing only on diarrheal specimens (≥3 unformed stools in 24 hours). Testing formed stool guarantees false-positive results due to asymptomatic colonization (present in 5-15% of hospitalized adults) and unnecessary treatment.
  • •Use a two-step diagnostic algorithm as the standard of care. Step 1: Screen with glutamate dehydrogenase (GDH) EIA. If GDH is negative, CDI is ruled out (negative predictive value >95%). Step 2: If GDH positive, perform toxin A/B EIA. A positive toxin EIA confirms CDI. A negative toxin EIA with positive GDH is discordant, perform NAAT as tiebreaker. If NAAT positive, treat as CDI; if negative, consider alternative diagnoses.
  • •Recognize that NAAT alone cannot distinguish infection from colonization, it detects the tcdB gene, not free toxin. Toxin EIA positivity correlates with more severe disease and higher recurrence rates compared with NAAT-positive-only cases (adjusted OR for 30-day mortality 1.56, 95% CI 1.24-1.96).
  • •Do not test for cure. Repeat stool testing within 2 weeks of a positive result is discouraged because nucleic acid and antigen can persist for weeks after clinical resolution.
  • •Assess severity immediately using the IDSA/SHEA criteria: non-severe (WBC ≤15,000 cells/μL and serum creatinine <1.5 mg/dL), severe (WBC >15,000 cells/μL or creatinine ≥1.5 mg/dL), and fulminant (hypotension, shock, ileus, or megacolon). Fulminant CDI carries a 30-40% mortality rate.
  • •Order abdominal CT when severe or complicated CDI is suspected, look for colonic wall thickening, thumbprinting, pancolitis, or toxic megacolon (transverse colon diameter >6 cm). Flexible sigmoidoscopy reveals pseudomembranes (yellow-white plaques) which are pathognomonic but absent in up to 30% of cases.
  • •Consider alternative diagnoses when diarrhea persists despite appropriate therapy: non-CDI antibiotic-associated diarrhea, IBD flare, other enteric pathogens (Salmonella, Shigella, Campylobacter, norovirus), ischemic colitis, or medication-induced diarrhea (laxatives, tube feeds, magnesium-containing antacids).
  • •In patients with IBD, test all diarrheal flares for CDI, up to 30% of IBD patients with diarrhea are colonized with toxigenic C. difficile. Stool IL-1β and anti-toxin antibodies may help differentiate infection from colonization.
  • •Assess recurrence risk using validated factors: age ≥65, severe CDI at presentation, immunocompromise, concomitant systemic antibiotics, PPIs, and prior CDI history. The BEYOND score (multi-marker risk model) can further stratify patients who may benefit from bezlotoxumab.

Management

  • •For any initial episode of CDI (non-severe or severe), initiate fidaxomicin 200 mg orally twice daily for 10 days, this is the IDSA/SHEA 2021 strong recommendation over vancomycin, driven by a 40-50% relative reduction in recurrence (absolute risk reduction ~10%, NNT=10) due to its narrow spectrum and microbiome-sparing profile.
  • •If fidaxomicin is unavailable or cost-prohibitive, use oral vancomycin 125 mg four times daily for 10 days as first-line for severe disease, or as alternative for non-severe. Vancomycin achieves clinical cure in ~90% but has a higher recurrence rate (~20-25%) than fidaxomicin (~15%).
  • •Do not use metronidazole for initial therapy unless neither fidaxomicin nor vancomycin is accessible. Metronidazole is inferior for sustained cure and is associated with higher recurrence rates (conditional recommendation, moderate-quality evidence).
  • •For fulminant CDI (hypotension, shock, ileus, megacolon), transfer to ICU immediately. Give oral vancomycin 500 mg four times daily via NG tube PLUS intravenous metronidazole 500 mg every 8 hours. If ileus prevents oral delivery, administer vancomycin 500 mg in 100 mL normal saline per rectum as a retention enema every 6-12 hours.
  • •Discontinue the inciting antibiotic whenever possible. If concomitant antibiotics are required for other infections, narrow the spectrum and use agents with the lowest CDI risk (e.g., doxycycline, aminoglycosides). Avoid PPIs unless a clear indication exists, PPIs independently increase CDI risk (OR 2.1) and synergize with antibiotics (OR 12.5).
  • •Do not use antimotility agents (loperamide, diphenoxylate-atropine) as monotherapy, they may precipitate toxic megacolon by retaining toxin in the colon. Antimotility agents can be considered only in combination with effective anti-CDI antibiotics and when obstruction has been excluded, though this is not generally recommended.
  • •Monitor clinical response, defined by resolution of diarrhea (≤3 unformed stools/day) and normalization of fever and abdominal tenderness, typically within 3-5 days. Do not perform a test of cure after treatment.
  • •For patients with no response after 5-7 days of appropriate therapy, re-confirm the diagnosis (repeat stool testing), switch agents (fidaxomicin to vancomycin or vice versa), evaluate for ileus/megacolon, and obtain urgent surgical consultation if no improvement after 48-72 hours of escalation.
  • •For first recurrence after a vancomycin-treated initial episode, treat with fidaxomicin 200 mg PO BID × 10 days. If the initial episode was fidaxomicin-treated, use vancomycin for the first recurrence. Consider adding bezlotoxumab 10 mg/kg IV as a single dose during antibiotic therapy for patients at high risk for multiple recurrences (age ≥65, severe CDI, immunocompromise, concomitant systemic antibiotics, prior CDI in 6 months).
  • •For multiply recurrent CDI (≥3 episodes), refer for fecal microbiota transplantation (FMT). A 2025 meta-analysis found FMT superior to vancomycin alone for preventing recurrence (RR 0.42, 95% CI 0.30-0.58; NNT=3). FMT is not first-line for a first episode or first recurrence.
  • •For patients with recent CDI (within 180 days) who require a new systemic antibiotic, consider secondary prophylaxis with oral vancomycin 125 mg PO BID for the duration of the antibiotic course plus 7 days. A 2025 RCT showed recurrence rates of 7.3% vs. 19.7% (RR 0.37; NNT=9).
  • •Do not routinely prescribe a vancomycin taper after a standard 10-day course, a 2026 RCT found no difference in recurrence between a 4-week taper and a 2-week pulse (20.5% vs 22.0%; RR 0.93). Do not routinely use probiotics for treatment or prevention of CDI, a large RCT found no benefit and a signal for probiotic-associated infections in critically ill patients.
  • •Initiate contact precautions (gown and glove) for all patients with suspected or confirmed CDI. Hand hygiene with soap and water is preferred over alcohol-based hand rubs, as C. difficile spores are alcohol-resistant. Use sporicidal agents (e.g., 1:10 bleach solution) for environmental cleaning.
  • •In immunocompromised patients (solid organ transplant, HSCT, IBD, cancer), fidaxomicin is preferred over vancomycin for initial episodes (composite outcome HR 0.62, 95% CI 0.41-0.94). FMT is safe and effective for recurrent CDI in this population. In IBD patients, test all diarrheal flares for CDI.
  • •In pediatric patients, metronidazole (30 mg/kg/day divided q6h, max 2 g/day) remains an option for mild-moderate first episodes. Vancomycin (40 mg/kg/day divided q6h, max 2 g/day) is used for severe disease. Fidaxomicin is not approved for children <6 months.
  • •In pregnancy, treat with metronidazole or vancomycin (both safe). Fidaxomicin safety is not established. Avoid FMT due to theoretical risks. Treat before delivery if possible.
  • •Refer for surgical consultation in any patient with fulminant CDI who does not improve within 24-48 hours of medical therapy. Total abdominal colectomy with end ileostomy or diverting loop ileostomy with colonic lavage may be life-saving. Indications include toxic megacolon, perforation, or refractory shock.
  • •Transition to outpatient management when the patient is hemodynamically stable, tolerating oral intake, and having ≤3 unformed stools/day without significant abdominal pain. Ensure a clear discharge plan for the full 10-day antibiotic course and arrange close follow-up for recurrence monitoring.

Board Review — High Yield

  • •Spore-forming anaerobe, C. difficile produces toxin A and toxin B that inactivate Rho GTPases, disrupting colonic epithelial tight junctions.
  • •Ribotype 027 (BI/NAP1/027), hypervirulent strain with higher toxin production, binary toxin (CDT), and fluoroquinolone resistance; now declining, replaced by ribotype 106 in some regions.
  • •Two-step testing algorithm, GDH screening → toxin EIA confirmation; NAAT as tiebreaker. NAAT alone overdiagnoses colonization.
  • •Antibiotic risk hierarchy, Clindamycin (OR 3.22) > fluoroquinolones (OR 2.65) > cephalosporins (OR 2.35). PPI + antibiotic synergy: OR 12.5.
  • •IDSA/SHEA severity, severe = WBC >15,000 or creatinine ≥1.5 mg/dL; fulminant = hypotension, ileus, megacolon.
  • •Fidaxomicin first-line, 200 mg PO BID × 10 days; reduces recurrence by ~10% vs vancomycin (NNT=10) via microbiome-sparing mechanism.
  • •Bezlotoxumab, monoclonal anti-toxin B antibody; single 10 mg/kg IV dose during antibiotic therapy for high-risk recurrence patients.
  • •Recurrence cycle, 20-30% after first episode; 40-60% after each subsequent recurrence. FMT (NNT=3) indicated for ≥3 recurrences.
  • •Fulminant CDI management, IV metronidazole + oral vancomycin (via NG tube or rectal enema if ileus); urgent surgical consult.
  • •Sporicidal cleaning, 1:10 bleach solution; soap and water (not alcohol hand rub) for hand hygiene.
  • •Secondary prophylaxis, vancomycin 125 mg PO BID during subsequent antibiotics in patients with recent CDI (≤180 days) reduces recurrence (NNT=9).

Deep Dive — Evidence Details

References

  1. [1]

    Johnson S, Lavergne V, Skinner AM et al.. “Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34164674 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  2. [2]

    Johnson S, Lavergne V, Skinner AM et al.. “Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34492699 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  3. [3]

    Drekonja DM, Shaukat A, Huang Y et al.. “A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39271107 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Complications
  4. [4]

    Okhuysen PC, Ramesh MS, Louie T et al.. “A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38305378 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  5. [5]

    Feuerstadt P, Chopra T, Knapple W et al.. “PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39180326 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Complications
  6. [6]

    Garey KW, McPherson J, Dinh AQ et al.. “Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35134880 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Complications
  7. [7]

    Feuerstadt P, Louie TJ, Lashner B et al.. “SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.” The New England journal of medicine (2022). PMID: 35045228 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric and Acute Management, Complications
  8. [8]

    Dubberke ER, Puckett JT, Obi EN et al.. “Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes.” Open forum infectious diseases (2022). PMID: 36267250 ↗

    L2GUIDELINECited in: Definition, Classification and Causative Organisms
  9. [9]

    Beniwal-Patel P, Stein DJ, Munoz-Price LS. “The Juncture Between Clostridioides difficile Infection and Inflammatory Bowel Diseases.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30689770 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Complications
  10. [10]

    Lavoie T, Appaneal HJ, LaPlante KL. “Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051964 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  11. [11]

    Alshannaq AF, Kates AE, Keating JA et al.. “Diverse Sources and Latent Reservoirs of Community-Associated Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39215602 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  12. [12]

    Gonzales-Luna AJ, Carlson TJ, Garey KW. “Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051970 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Complications
  13. [13]

    Le TM, Eubank TA, McKelvey AM et al.. “Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites.” Antimicrobial agents and chemotherapy (2024). PMID: 39503488 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  14. [14]

    Louie T, Golan Y, Khanna S et al.. “VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA (2023). PMID: 37060545 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric and Acute Management, Complications
  15. [15]

    Khanna S, Allegretti JR, Hashash JG et al.. “AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review.” Gastroenterology (2026). PMID: 42138670 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Complications, Prevention, Infection Control and Special Populations
  16. [16]

    Yan AP, Yi M, Patel P et al.. “Use of Electronic Health Records to Benchmark Clinical Practice Guideline-Consistent Care in Pediatric Oncology.” JCO clinical cancer informatics (2026). PMID: 41886707 ↗

    L4GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Prevention, Infection Control and Special Populations
  17. [17]

    Jo J, Hu C, Horvath TD et al.. “Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin.” Antimicrobial agents and chemotherapy (2025). PMID: 39819014 ↗

    L1TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
  18. [18]

    Jo J, Carlson TJ, Hu C et al.. “Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial.” The Journal of antimicrobial chemotherapy (2025). PMID: 40796204 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management
  19. [19]

    Di Bella S, Sanson G, Monticelli J et al.. “Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.” Clinical microbiology reviews (2024). PMID: 38421181 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management
  20. [20]

    Yadegar A, Bar-Yoseph H, Monaghan TM et al.. “Fecal microbiota transplantation: current challenges and future landscapes.” Clinical microbiology reviews (2024). PMID: 38717124 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  21. [21]

    Veve MP, Kenney RM, Aljundi AM et al.. “Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States.” Antimicrobial agents and chemotherapy (2025). PMID: 40035548 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  22. [22]

    DeFilipp Z, Bloom PP, Torres Soto M et al.. “Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.” The New England journal of medicine (2019). PMID: 31665575 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship, Complications
  23. [23]

    Aràjol C, González Suárez B, Bonilla Moreno M et al.. “Clostridioides difficile infection: Position paper of the Catalan Society of Gastroenterology.” Gastroenterologia y hepatologia (2026). PMID: 41547475 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  24. [24]

    Rode AA, Duboc H, Lamazière A et al.. “Re-establishing bile acid composition after treatment of recurrent Clostridioides difficile infection with fecal microbiota transplantation compared with oral vancomycin or a 12-strain bacterial mixture.” Gut microbes (2026). PMID: 41997890 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management
  25. [25]

    Eriksen LL, Støy S, Mejlby Hansen M et al.. “Dynamics in Circulating Immune Cell Subsets After Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.” Clinical and translational gastroenterology (2026). PMID: 41738638 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Complications
  26. [26]

    Bryant JA, Vulić M, Walsh EA et al.. “The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.” Nature medicine (2026). PMID: 41491103 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms
  27. [27]

    Salvador BC, Gomes DL, Araujo AGS et al.. “Systematic review: Accuracy of diagnostic methods for Clostridioides difficile infection.” Anaerobe (2026). PMID: 41833705 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  28. [28]

    Chernova VO, van Prehn J, Groenewegen B et al.. “Biovigilance in Faecal Microbiota Transplantation: 7-Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events.” United European gastroenterology journal (2026). PMID: 42283215 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
  29. [29]

    Duricek M, Bartos H, Halmova K et al.. “ESBL positivity as an independent predictor of Clostridioides difficile infection: a retrospective cohort study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42070626 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  30. [30]

    Brown KA, Coburn B, Hernandez A et al.. “Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study.” The Journal of infectious diseases (2026). PMID: 41830216 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  31. [31]

    Gong J-J, Huang I-H, Hung Y et al.. “Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention.” Antimicrobial agents and chemotherapy (2025). PMID: 40525407 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  32. [32]

    Webb BJ, Subramanian A, Lopansri B et al.. “Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.” Antimicrobial agents and chemotherapy (2020). PMID: 31964789 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  33. [33]

    De Wolfe TJ, Kates AE, Barko L et al.. “Modified Mouse Model of Clostridioides difficile Infection as a Platform for Probiotic Efficacy Studies.” Antimicrobial agents and chemotherapy (2019). PMID: 30988143 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Prognosis and Natural History
  34. [34]

    Jorgensen SCJ, Trinh TD, Zasowski EJ et al.. “Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 31932379 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  35. [35]

    Bassères E, Eubank TA, Begum K et al.. “Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile.” Antimicrobial agents and chemotherapy (2024). PMID: 38364016 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  36. [36]

    Wieczorkiewicz JT, Skinner AM, Cheknis A et al.. “Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures.” Antimicrobial agents and chemotherapy (2024). PMID: 38953622 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  37. [37]

    McPherson J, Hu C, Begum K et al.. “Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection.” Antimicrobial agents and chemotherapy (2022). PMID: 35862742 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  38. [38]

    Buckley AM, Moura IB, Altringham J et al.. “The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection.” The Journal of antimicrobial chemotherapy (2021). PMID: 34561709 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
  39. [39]

    Ranganath N, Tabaja H, Nair VO et al.. “Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections.” The Journal of antimicrobial chemotherapy (2025). PMID: 40470775 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  40. [40]

    Duricek M, Halmova K, Krutova M et al.. “Is shorter also better in the treatment of Clostridioides difficile infection?” The Journal of antimicrobial chemotherapy (2024). PMID: 38661207 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  41. [41]

    Saydan S, Schwab F, Holstiege J et al.. “Surveillance of Clostridioides difficile on hospital admission and outpatient antibiotic use in Germany-a 9 year ecological analysis.” The Journal of antimicrobial chemotherapy (2025). PMID: 39821312 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
  42. [42]

    Boton N, Patel PK, Beekmann SE et al.. “Clinician Management Preferences for Clostridioides difficile Infection in Adults: A 2024 Emerging Infections Network Survey.” Open forum infectious diseases (2025). PMID: 40599494 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management
  43. [43]

    Dubberke ER, Li Q, Obi EN et al.. “A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection.” Open forum infectious diseases (2024). PMID: 39355263 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  44. [44]

    Carlson TJ, Gonzales-Luna AJ, Nebo K et al.. “Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection.” Open forum infectious diseases (2020). PMID: 33209956 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History
  45. [45]

    Chua HC, Eubank TA, Lee A et al.. “Defining Fulminant Clostridioides difficile Infections: Assessing the Utility of Hypotension as a Diagnostic Criterion.” Open forum infectious diseases (2025). PMID: 39896986 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  46. [46]

    Yin J, Kociolek LK, Same RG et al.. “Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections.” Open forum infectious diseases (2019). PMID: 31950069 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  47. [47]

    Du T, Silva A, Choi KB et al.. “Characterization of Adult and Pediatric Healthcare-Associated and Community-Associated Clostridioides difficile Infections, Canada, 2015-2022.” Emerging infectious diseases (2025). PMID: 40439410 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  48. [48]

    Conlon-Bingham GM, Aldeyab M, Scott M et al.. “Effects of Antibiotic Cycling Policy on Incidence of Healthcare-Associated MRSA and Clostridioides difficile Infection in Secondary Healthcare Settings.” Emerging infectious diseases (2019). PMID: 30561306 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  49. [49]

    Rizzardi K, Norén T, Aspevall O et al.. “National Surveillance for Clostridioides difficile Infection, Sweden, 2009-2016.” Emerging infectious diseases (2018). PMID: 30124193 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  50. [50]

    Kim MH, Kim J, Ra H et al.. “Identifying Contact Time Required for Secondary Transmission of Clostridioides difficile Infections by Using Real-Time Locating System.” Emerging infectious diseases (2024). PMID: 38666567 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  51. [51]

    Prosty C, Hanula R, Katergi K et al.. “Clinical Outcomes and Management of NAAT-Positive/Toxin-Negative Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37648251 ↗

    L1SR_OBSCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  52. [52]

    Donskey CJ, Dubberke ER, Klein NP et al.. “CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39180325 ↗

    L1RCTCited in: Microbiology and Pathogenesis, Empiric and Acute Management, Complications
  53. [53]

    Louie T, Ribble W, Boccumini L et al.. “Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.” The Lancet. Infectious diseases (2026). PMID: 41581516 ↗

    L1RCTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  54. [54]

    Guery B, Georgopali A, Karas A et al.. “Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.” The Journal of antimicrobial chemotherapy (2020). PMID: 31960058 ↗

    L1RCTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  55. [55]

    Fitzpatrick F, Safdar N, van Prehn J et al.. “How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed?” The Lancet. Infectious diseases (2022). PMID: 35617982 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  56. [56]

    Redmond SN, Cadnum JL, Jencson AL et al.. “Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40036727 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  57. [57]

    Kar OB, Freedberg DE. “The phases of Clostridioides difficile infection in the United States: the history and epidemiology of CDI from 1935 to present.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42284457 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Antimicrobial Resistance and Stewardship
  58. [58]

    Villafuerte Gálvez JA, Pollock NR, Alonso CD et al.. “Stool Interleukin-1β Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35906836 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  59. [59]

    Doolan CP, Louie T, Lata C et al.. “Latent Class Analysis for the Diagnosis of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33053174 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  60. [60]

    Kelly CP, Chen X, Williams D et al.. “Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31211839 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  61. [61]

    Barbar R, Brazelton JN, Carroll KC et al.. “Molecular Epidemiology and Genetic Relatedness of Clostridioides difficile Isolates in Pediatric Oncology and Transplant Patients Using Whole Genome Sequencing.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35675378 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  62. [62]

    Guh AY, Hatfield KM, Winston LG et al.. “Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30615074 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  63. [63]

    Wilcox MH, Rahav G, Dubberke ER et al.. “Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.” Open forum infectious diseases (2019). PMID: 31375837 ↗

    L2TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  64. [64]

    Schechner V, Fallach N, Braun T et al.. “Antibiotic exposure and the risk of hospital-acquired diarrhoea and Clostridioides difficile infection: a cohort study.” The Journal of antimicrobial chemotherapy (2021). PMID: 33969419 ↗

    L3COHORTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  65. [65]

    Abou Chakra CN, Gagnon A, Lapointe S et al.. “The Strain and the Clinical Outcome of Clostridioides difficile Infection: A Meta-analysis.” Open forum infectious diseases (2024). PMID: 38524230 ↗

    L1SR_OBSCited in: Microbiology and Pathogenesis, Empiric and Acute Management, Prognosis and Natural History
  66. [66]

    Wilcox MH, McGovern BH, Hecht GA. “The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis.” Open forum infectious diseases (2020). PMID: 32405509 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric and Acute Management, Complications
  67. [67]

    Bansal D, Pahil S, Chatterjee A et al.. “Clostridioides difficile infection in inflammatory bowel disease: an observational study in flares of ulcerative colitis and a South Asian region-specific systematic review and meta-analysis.” Therapeutic advances in gastroenterology (2026). PMID: 42136876 ↗

    L2SR_OBSCited in: Microbiology and Pathogenesis
  68. [68]

    Lee SH, Kim TY, Huh HJ et al.. “Clinical outcomes of toxin-positive versus toxin-negative/NAAT-positive Clostridioides difficile infection in South Korea: a single-center retrospective cohort study.” BMC infectious diseases (2026). PMID: 42168920 ↗

    L3COHORTCited in: Microbiology and Pathogenesis
  69. [69]

    Rodríguez RG, Rodríguez MJP, López APG et al.. “Incidence of hospital-acquired toxin-producing clostridioides difficile infection between the pre-pandemic (2017-2019) and pandemic (2020-2022): a retrospective cohort study.” Archives of public health = Archives belges de sante publique (2026). PMID: 41721370 ↗

    L3COHORTCited in: Microbiology and Pathogenesis
  70. [70]

    Liu Y, Ma L, Cheng J et al.. “Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms.” Antimicrobial agents and chemotherapy (2023). PMID: 37223895 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Empiric and Acute Management
  71. [71]

    Costa DVS, Pham NVS, Hays RA et al.. “Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.” Antimicrobial agents and chemotherapy (2022). PMID: 35861541 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Severity Assessment and Risk Stratification, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  72. [72]

    Escudero-Sánchez R, Rubio Martín E, Vizcarra P et al.. “Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36861316 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  73. [73]

    Murray B, Wolfe C, Marra A et al.. “In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2020). PMID: 32285102 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  74. [74]

    Buckley AM, Altringham J, Clark E et al.. “Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model.” The Journal of antimicrobial chemotherapy (2021). PMID: 32929459 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  75. [75]

    Chilton CH, Crowther GS, Miossec C et al.. “Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model.” The Journal of antimicrobial chemotherapy (2020). PMID: 32097465 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  76. [76]

    Ryan K, Kaufer A, Jayawardena M et al.. “Clostridioides difficile laboratory testing algorithms and performance: a review of the Royal College of Pathologists of Australasia Quality Assurance Programs external quality assessments for C. difficile.” Pathology (2026). PMID: 41760493 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation
  77. [77]

    Wang R, Li X, Zhang T. “Current status and future perspectives of fecal immunological markers in the differential diagnosis of Clostridioides difficile infection in children.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41723281 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  78. [78]

    Sanchez-Ramos L, Preis R, Romero R. “Prophylactic antibiotics to prevent postcesarean infection: which antimicrobial, when, how, and why?” American journal of obstetrics and gynecology (2025). PMID: 41485837 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  79. [79]

    Young MK, Leslie JL, Madden GR et al.. “Binary Toxin Expression by Clostridioides difficile Is Associated With Worse Disease.” Open forum infectious diseases (2022). PMID: 35146046 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  80. [80]

    Carlson TJ, Endres BT, Le Pham J et al.. “Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection.” Open forum infectious diseases (2020). PMID: 31993458 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History
  81. [81]

    Hilt EE, Vaughn BP, Galdys AL et al.. “Impact of the Reverse 2-Step Algorithm for Clostridioides difficile Testing in the Microbiology Laboratory on Hospitalized Patients.” Open forum infectious diseases (2024). PMID: 38756762 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  82. [82]

    Jorgensen SCJ, Trinh TD, Zasowski EJ et al.. “Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections.” Open forum infectious diseases (2019). PMID: 31890725 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  83. [83]

    Wilcox MH, Cornely OA, Guery B et al.. “Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study.” Open forum infectious diseases (2019). PMID: 31723569 ↗

    L1OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation
  84. [84]

    Pender M, Throneberry SK, Grisel N et al.. “Syndromic Panel Testing Among Patients With Infectious Diarrhea: The Challenge of Interpreting Clostridioides difficile Positivity on a Multiplex Molecular Panel.” Open forum infectious diseases (2023). PMID: 37711280 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  85. [85]

    Carlson TJ, Gonzales-Luna AJ, Wilcox MF et al.. “Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use.” Open forum infectious diseases (2021). PMID: 34646906 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  86. [86]

    Golan Y, DuPont HL, Aldomiro F et al.. “Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.” Open forum infectious diseases (2020). PMID: 32685606 ↗

    L1OTHERCited in: Microbiology and Pathogenesis
  87. [87]

    Preechakawin N, Suttikulsombat M, Kiratisin P et al.. “Adjunctive use of Saccharomyces boulardii versus bismuth subsalicylate in the management of non-Clostridioides difficile nosocomial diarrhea in severely ill patients: a three-arm randomized controlled trial.” Translational gastroenterology and hepatology (2026). PMID: 41675330 ↗

    L1RCTCited in: Microbiology and Pathogenesis
  88. [88]

    Mehta P, Nahass RG, Brunetti L. “Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32386313 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  89. [89]

    Poirier D, Gervais P, Fuchs M et al.. “Predictors of Clostridioides difficile Infection Among Asymptomatic, Colonized Patients: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31290544 ↗

    L3COHORTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prevention, Infection Control and Special Populations
  90. [90]

    Slimings C, Riley TV. “Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update.” The Journal of antimicrobial chemotherapy (2021). PMID: 33787887 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  91. [91]

    Carlson TJ, Gonzales-Luna AJ. “Utilizing antibiotics to prevent Clostridioides difficile infection: does exposure to a risk factor decrease risk? A systematic review.” The Journal of antimicrobial chemotherapy (2020). PMID: 32696044 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  92. [92]

    Dulhunty JM, Brett SJ, De Waele JJ et al.. “Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.” JAMA (2024). PMID: 38864155 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  93. [93]

    Saravolatz L, Gandhi TN, Vaughn VM et al.. “Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40601818 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  94. [94]

    Sahrmann JM, Olsen MA, Stwalley D et al.. “Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36285546 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  95. [95]

    Taniguchi J, Aso S, Matsui H et al.. “Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492536 ↗

    L3COHORTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  96. [96]

    Oltolini C, Piekarska A, Signori A et al.. “Clostridioides difficile infection in non-transplanted adults with haematological malignancy: Systematic review and meta-analysis on behalf of European Conference on Infections in Leukemia (ECIL) and Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT).” Blood reviews (2026). PMID: 42106226 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric and Acute Management, Prognosis and Natural History
  97. [97]

    Landivar MC, Hartmann Rost I, Carvalho Kilson A et al.. “Efficacy of fluoroquinolone prophylaxis during induction phase in children with acute lymphoblastic leukemia: a systematic review and meta-analysis.” European journal of pediatrics (2026). PMID: 42065773 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  98. [98]

    Zhao Y, He X, Hu Y et al.. “Impact of the COVID-19 pandemic on the incidence of Clostridioides difficile infection based on hospital surveillance data: a systematic review and meta-analysis.” Antimicrobial resistance and infection control (2026). PMID: 41933426 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  99. [99]

    Skjøt-Arkil H, Rune Nanthan K, Chen M et al.. “Carrier prevalence of Clostridioides difficile in emergency departments and the association of prior antibiotic consumption: a combined cross-sectional and nested case-control study.” The Journal of antimicrobial chemotherapy (2023). PMID: 37409612 ↗

    L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  100. [100]

    Guh AY, Mu Y, Winston LG et al.. “Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.” The New England journal of medicine (2020). PMID: 32242357 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  101. [101]

    Chen YC, Kuo YC, Chen MC et al.. “Case-Control Study of Clostridium innocuum Infection, Taiwan.” Emerging infectious diseases (2022). PMID: 35195517 ↗

    L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  102. [102]

    Okafor CM, Clogher P, Olson D et al.. “Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020.” Emerging infectious diseases (2023). PMID: 37081745 ↗

    L2REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  103. [103]

    Daniel F, Abdallah B, Chaitou AR et al.. “Association between postoperative Clostridioides difficile infection and outcomes following pancreatoduodenectomy for pancreatic cancer: a national cohort study.” Surgical endoscopy (2026). PMID: 42257924 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors
  104. [104]

    Rohde AM, Kern WV, Behnke M et al.. “All-cause mortality and risk factors for death in patients with Clostridioides difficile infections: a prospective multi-centre cohort study in six German university hospitals, 2016-2020.” The Journal of hospital infection (2026). PMID: 41724443 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors
  105. [105]

    Zhang J, Chen L, Gomez-Simmonds A et al.. “Antibiotic-Specific Risk for Community-Acquired Clostridioides difficile Infection in the United States from 2008 to 2020.” Antimicrobial agents and chemotherapy (2022). PMID: 36377887 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  106. [106]

    Rhodes NJ, Jozefczyk CC, Moore WJ et al.. “Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2021). PMID: 33875439 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  107. [107]

    Tydeman F, Craine N, Kavanagh K et al.. “Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales.” The Journal of antimicrobial chemotherapy (2021). PMID: 34151964 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  108. [108]

    Moreels N, Boven A, Gressani O et al.. “The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.” The Journal of antimicrobial chemotherapy (2024). PMID: 38267263 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management
  109. [109]

    Kipnis M, Schwab F, Kramer TS et al.. “Incidence of healthcare-associated Clostridioides difficile infections and association with ward-level antibiotic consumption in a German university hospital: an ecological study.” The Journal of antimicrobial chemotherapy (2019). PMID: 31098633 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  110. [110]

    Yamamoto S, Shiroshita A, Kataoka Y et al.. “Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study.” Open forum infectious diseases (2025). PMID: 40134633 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Prognosis and Natural History
  111. [111]

    Ilett EE, Helleberg M, Reekie J et al.. “Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.” Open forum infectious diseases (2019). PMID: 30949533 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  112. [112]

    Li X, Xiao F, Wang X et al.. “Gut Microbial and Metabolic Features Associated With Clostridioides difficile Infection Recurrence in Children.” Open forum infectious diseases (2024). PMID: 39319090 ↗

    L1OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management
  113. [113]

    Olsen MA, Keller MR, Stwalley D et al.. “Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 37547851 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  114. [114]

    Sanchez E, Krantz EM, Escobar ZK et al.. “Epidemiology and Outcomes of Recurrent C Difficile Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study.” Open forum infectious diseases (2024). PMID: 39450393 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Prevention, Infection Control and Special Populations
  115. [115]

    Williams MJ, Atienza S, Franzen E et al.. “Evaluation of Primary Oral Vancomycin Prophylaxis Against Clostridioides difficile Infection During Autologous Stem Cell Transplantation.” Open forum infectious diseases (2024). PMID: 39498172 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prevention, Infection Control and Special Populations
  116. [116]

    Johnson TM, Howard AH, Miller MA et al.. “Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients.” Open forum infectious diseases (2021). PMID: 34262988 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  117. [117]

    Tartof SY, Schmidt MA, Contreras R et al.. “Burden of Medically Attended Diarrhea and Outpatient Clostridioides difficile Infection Among Persons in 2 Large Integrated Healthcare Settings, 2016-2021.” Open forum infectious diseases (2024). PMID: 38250203 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management
  118. [118]

    Cornely OA, Mullane KM, Birch T et al.. “Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer.” Open forum infectious diseases (2020). PMID: 32099847 ↗

    L1OTHERCited in: Epidemiology, Transmission and Risk Factors
  119. [119]

    Du T, Choi KB, Silva A et al.. “Characterization of Healthcare-Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada, 2015-2019.” Emerging infectious diseases (2022). PMID: 35470794 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  120. [120]

    Guo CLT, Kwong TNY, Mak JWY et al.. “Trends in Incidence and Clinical Outcomes of Clostridioides difficile Infection, Hong Kong.” Emerging infectious diseases (2021). PMID: 34812719 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  121. [121]

    Miller AC, Arakkal AT, Sewell DK et al.. “Risk for Asymptomatic Household Transmission of Clostridioides difficile Infection Associated with Recently Hospitalized Family Members.” Emerging infectious diseases (2022). PMID: 35447064 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  122. [122]

    Ramirez JA, Angulo FJ, Carrico RM et al.. “Misdiagnosis of Clostridioides difficile Infections by Standard-of-Care Specimen Collection and Testing among Hospitalized Adults, Louisville, Kentucky, USA, 2019-20201.” Emerging infectious diseases (2023). PMID: 37080953 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  123. [123]

    Dunn AN, Radakovich N, Ancker JS et al.. “The Impact of Clinical Decision Support Alerts on Clostridioides difficile Testing: A Systematic Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32060501 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Complications
  124. [124]

    Doolan CP, Sahragard B, Leal J et al.. “Clostridioides difficile Near-Patient Testing Versus Centralized Testing: A Pragmatic Cluster Randomized Crossover Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36718646 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  125. [125]

    Perry DA, Shirley D, Micic D et al.. “External Validation and Comparison of Clostridioides difficile Severity Scoring Systems.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34459885 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup, Complications, Prognosis and Natural History
  126. [126]

    Lin MY, Stein BD, Kothadia SM et al.. “Impact of Mandatory Infectious Disease Specialist Approval on Hospital-Onset Clostridioides difficile Infection Rates and Testing Appropriateness.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37157903 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  127. [127]

    Shenoy ES, Macy E, Rowe T et al.. “Evaluation and Management of Penicillin Allergy: A Review.” JAMA (2019). PMID: 30644987 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Antimicrobial Resistance and Stewardship, Complications
  128. [128]

    Eubank TA, Jo J, Alam MJ et al.. “Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study.” The Lancet. Microbe (2025). PMID: 40516571 ↗

    L1RCTCited in: Clinical Presentation
  129. [129]

    Wang C, Gao H, Zhu C et al.. “Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses.” BMJ evidence-based medicine (2026). PMID: 42303374 ↗

    L5SR_OBSCited in: Clinical Presentation, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  130. [130]

    Kozák M, Majoros L, Panyiczki Z et al.. “Severe vitamin K deficiency-associated coagulopathy triggered by Clostridioides difficile infection and antibiotic-associated dysbiosis: A case report and literature review.” Infection (2026). PMID: 41563580 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  131. [131]

    AlAwadhi HK, Hyesoo Chang N, Jogendran M et al.. “Gastroenterology/Hepatology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974014 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  132. [132]

    Guh AY, Li R, Korhonen L et al.. “Characteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences.” Open forum infectious diseases (2024). PMID: 38577028 ↗

    L2OTHERCited in: Clinical Presentation
  133. [133]

    Darkoh C, Keita K, Odo C et al.. “Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35016207 ↗

    L4OTHERCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  134. [134]

    Stevens VW, Khader K, Echevarria K et al.. “Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31504328 ↗

    L2OTHERCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  135. [135]

    Turner NA, Krishnan J, Nelson A et al.. “Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37279965 ↗

    L2OTHERCited in: Diagnosis and Workup
  136. [136]

    Crotty M, Devall H, Cook N et al.. “Short Versus Long Antibiotic Duration in Streptococcus pneumoniae Bacteremia.” Open forum infectious diseases (2024). PMID: 39257675 ↗

    L2TRIAL_NONRANDOMCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  137. [137]

    Rabiee MH, Abdolmohammadi Khiav L, Fallah Mehrabadi MH. “Prevalence of Clostridioides difficile contamination in healthcare and non-healthcare environments: a global systematic review and meta-analysis.” International health (2026). PMID: 41127891 ↗

    L1SR_OBSCited in: Diagnosis and Workup
  138. [138]

    Barbero AM, Moriconi ND, Palma S et al.. “Epidemiology of Clostridioides difficile Infection in Argentina and Associated Risk Factors Evaluated Through a Meta-Analysis.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353652 ↗

    L3SR_OBSCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  139. [139]

    Huang TC, Kou T, Kuo CJ et al.. “Enteric opportunistic infections in patients with inflammatory bowel disease receiving biologic therapies: a retrospective cohort study.” Gut pathogens (2025). PMID: 41423627 ↗

    L2COHORTCited in: Diagnosis and Workup
  140. [140]

    Cusumano JA, Daffinee KE, Piehl EC et al.. “Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations.” Antimicrobial agents and chemotherapy (2022). PMID: 36154173 ↗

    L5OTHERCited in: Diagnosis and Workup
  141. [141]

    McPherson JK, Hurdle JG, Baker ML et al.. “The microbiome-restorative potential of ibezapolstat for the treatment of Clostridioides difficile infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae.” Antimicrobial agents and chemotherapy (2025). PMID: 39982073 ↗

    L5OTHERCited in: Diagnosis and Workup
  142. [142]

    Bassères E, Begum K, Lancaster C et al.. “In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2020). PMID: 32719870 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  143. [143]

    Kolte B, Nübel U. “Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.” The Journal of antimicrobial chemotherapy (2024). PMID: 38598696 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  144. [144]

    Boekhoud IM, Sidorov I, Nooij S et al.. “Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2021). PMID: 33876817 ↗

    L5OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  145. [145]

    Itogawa K, Narumoto O, Takeda K et al.. “Continuation of anti-tuberculosis therapy after Clostridioides difficile infection: a retrospective cohort study.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42296592 ↗

    L2COHORTCited in: Diagnosis and Workup, Empiric and Acute Management
  146. [146]

    Alkhushaym N, Alabbad R, Alqarni YS et al.. “Assessment of rifaximin and rifampicin resistance across Clostridioides difficile ribotypes: a systematic review and meta-analysis.” Letters in applied microbiology (2026). PMID: 41604218 ↗

    L1SR_OBSCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  147. [147]

    Meireles J, Leite S, de Castro Brandt AMT et al.. “High genetic similarity between Clostridioides difficile isolates from a woman with community-acquired infection and her dog.” Frontiers in public health (2026). PMID: 41584189 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  148. [148]

    Maeda M, Mori N, Hiraide M et al.. “Evaluation of Antibiotic Use Metrics as Predictors of Clostridioides difficile Infection Onset: A Single-Center, Case-Control Study Assessing the Days of Therapy and the Days of Antibiotic Spectrum Coverage.” Biological & pharmaceutical bulletin (2026). PMID: 41765474 ↗

    L3CASE_CONTROLCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  149. [149]

    Kaple CE, Cadnum JL, Redmond SN et al.. “A sensitive and reduced-cost culture medium for recovery of Clostridioides difficile isolates with reduced fidaxomicin susceptibility from stool.” Journal of clinical microbiology (2026). PMID: 42283494 ↗

    L5OTHERCited in: Diagnosis and Workup
  150. [150]

    Patterson WM, Fajnzylber J, Nero N et al.. “Diagnostic prediction models to identify patients at risk for healthcare-facility-onset Clostridioides difficile: A systematic review of methodology and reporting.” Infection control and hospital epidemiology (2023). PMID: 37665104 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  151. [151]

    Friedrichs A, Wenz R, Pape D et al.. “The effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study.” Infection (2025). PMID: 40569348 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  152. [152]

    Chen JH, Chiu CH, Chen CC et al.. “Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent Clostridioides difficile Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study.” Biomedicines (2024). PMID: 39061970 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification
  153. [153]

    Chen W, Liu Y, Zhang Y et al.. “Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.” BMC gastroenterology (2024). PMID: 39448963 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  154. [154]

    Wen BJ, Te LG, Liu XX et al.. “The value of fecal calprotectin in Clostridioides difficile infection: A systematic review.” Frontiers in physiology (2022). PMID: 35991191 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  155. [155]

    Li J, Yang J, Ouyang Z et al.. “Molecular typing and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease: A retrospective study.” Journal of global antimicrobial resistance (2025). PMID: 40287014 ↗

    L4COHORTCited in: Severity Assessment and Risk Stratification
  156. [156]

    Le PH, Chen CL, Kuo CJ et al.. “Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study.” The Kaohsiung journal of medical sciences (2025). PMID: 40091757 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification
  157. [157]

    Ressler AM, Patel A, Rao K. “Non-steroidal anti-inflammatory drugs are not associated with increased risk of Clostridioides difficile infection: A propensity-score-matched case-control study.” Anaerobe (2021). PMID: 34506930 ↗

    L3CASE_CONTROLCited in: Severity Assessment and Risk Stratification
  158. [158]

    Tariq R, Sethi A, Arunachalam S et al.. “Machine Learning Model Predicts Recurrent Clostridioides difficile Infection in Patients With Inflammatory Bowel Disease (Recur CDI-IBD).” The American journal of gastroenterology (2026). PMID: 41562450 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  159. [159]

    Rao K, Zhao Q, Bell J et al.. “An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37797310 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  160. [160]

    Young PJ, Bagshaw SM, Forbes AB et al.. “Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial.” JAMA (2020). PMID: 31950977 ↗

    L1RCTCited in: Empiric and Acute Management, Complications, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  161. [161]

    Johnstone J, Meade M, Lauzier F et al.. “Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial.” JAMA (2021). PMID: 34546300 ↗

    L1RCTCited in: Empiric and Acute Management, Complications, Prognosis and Natural History
  162. [162]

    Hirsch W, Enns EA, Khoruts A et al.. “Cost-effectiveness of Commercial or Traditional Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42274997 ↗

    L2OTHERCited in: Empiric and Acute Management, Prognosis and Natural History
  163. [163]

    Aby ES, Vaughn BP, Enns EA et al.. “Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35275989 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  164. [164]

    Alonso CD, Tillotson GS, Bidell MR et al.. “Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study.” Open forum infectious diseases (2025). PMID: 40177588 ↗

    L4TRIAL_NONRANDOMCited in: Empiric and Acute Management, Complications, Prevention, Infection Control and Special Populations
  165. [165]

    Phillips EC, Warren CA, Ma JZ et al.. “Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.” Antimicrobial agents and chemotherapy (2022). PMID: 35647645 ↗

    L3COHORTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  166. [166]

    Escudero-Sanchez R, Muriel García A, García Fernández S et al.. “Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.” The Journal of antimicrobial chemotherapy (2022). PMID: 35403189 ↗

    L3COHORTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  167. [167]

    Gonzales-Luna AJ, Skinner AM, Alonso CD et al.. “Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.” The Lancet. Infectious diseases (2023). PMID: 37062301 ↗

    L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  168. [168]

    Naz F, Petri WA. “Host Immunity and Immunization Strategies for Clostridioides difficile Infection.” Clinical microbiology reviews (2023). PMID: 37162338 ↗

    L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Prevention, Infection Control and Special Populations
  169. [169]

    Allegretti JR, Mullish BH, Kelly C et al.. “The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.” Lancet (London, England) (2019). PMID: 31379333 ↗

    L5REVIEW_NARRATIVECited in: Empiric and Acute Management
  170. [170]

    Saint-Lu N, Burdet C, Sablier-Gallis F et al.. “DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones.” Antimicrobial agents and chemotherapy (2019). PMID: 31636067 ↗

    L5OTHERCited in: Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  171. [171]

    Phan JR, Do DM, Truong MC et al.. “An Aniline-Substituted Bile Salt Analog Protects both Mice and Hamsters from Multiple Clostridioides difficile Strains.” Antimicrobial agents and chemotherapy (2021). PMID: 34780262 ↗

    L5OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  172. [172]

    Mason CS, Avis T, Hu C et al.. “The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic.” Antimicrobial agents and chemotherapy (2023). PMID: 37093023 ↗

    L5OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  173. [173]

    Hu X, Dong R, Huang S et al.. “CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.” Antimicrobial agents and chemotherapy (2023). PMID: 37052498 ↗

    L5OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  174. [174]

    Bishop EJ, Tiruvoipati R. “Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.” The Journal of antimicrobial chemotherapy (2022). PMID: 36441203 ↗

    L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  175. [175]

    Bassetti M, Cascio A, De Rosa FG et al.. “Management of Clostridioides difficile infection: an Italian Delphi consensus.” The Journal of antimicrobial chemotherapy (2024). PMID: 39008427 ↗

    L5OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  176. [176]

    Sun Y, Veccia D, Song G et al.. “Acid-Suppressive Therapy Choice and Risk of Treatment Escalation in Inflammatory Bowel Disease: A Real-World Comparative Retrospective Study to Inform Personalized Treatment.” Journal of personalized medicine (2026). PMID: 42042559 ↗

    L2COHORTCited in: Empiric and Acute Management
  177. [177]

    Mehta N, Goodenough D, Gupta NK et al.. “Recurrent Clostridioides difficile Infection and Outcome of Fecal Microbiota Transplantation Use: A Population-Based Assessment.” Open forum infectious diseases (2024). PMID: 38975247 ↗

    L2OTHERCited in: Empiric and Acute Management, Prognosis and Natural History
  178. [178]

    Stewart AG, Chen SCA, Hamilton K et al.. “Clostridioides difficile Infection: Clinical Practice and Health Outcomes in 6 Large Tertiary Hospitals in Eastern Australia.” Open forum infectious diseases (2023). PMID: 37274181 ↗

    L2OTHERCited in: Empiric and Acute Management
  179. [179]

    de la Villa S, Herrero S, Muñoz P et al.. “Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 36776780 ↗

    L2OTHERCited in: Empiric and Acute Management
  180. [180]

    Hunt A, Danziger LH, Johnson S et al.. “Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection.” Open forum infectious diseases (2024). PMID: 38665169 ↗

    L4OTHERCited in: Empiric and Acute Management
  181. [181]

    Deshpande A, Chen Y, Boye-Codjoe E et al.. “Adoption and Trends in Uptake of Updated ICD-10 Codes for Clostridioides difficile-A Retrospective Observational Study.” Open forum infectious diseases (2022). PMID: 36519119 ↗

    L4OTHERCited in: Empiric and Acute Management
  182. [182]

    Hirai J, Hanai Y. “Metronidazole versus Vancomycin for a Moderate Clostridioides difficile Infection Defined by the Japanese Severity Score (MN Criteria): A Propensity Score-Matched Cohort Study.” Internal medicine (Tokyo, Japan) (2026). PMID: 41922231 ↗

    L2COHORTCited in: Empiric and Acute Management
  183. [183]

    Yousef A, Wang N, Yousef M et al.. “Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth.” Journal of clinical medicine (2026). PMID: 42355617 ↗

    L2OTHERCited in: Empiric and Acute Management
  184. [184]

    Orzechowski D, Mroczkowska A, Bryła A et al.. “Clinical Considerations of Amikacin Pharmacotherapy in Adults-A Narrative Review with Focus on Safety and TDM.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353658 ↗

    L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  185. [185]

    Berry P, Bharadiya V, Pardi DS et al.. “Cost-effectiveness of Microbiota Restoration Therapies for Recurrent Clostridioides difficile Infection.” The American journal of gastroenterology (2026). PMID: 42329003 ↗

    L2OTHERCited in: Empiric and Acute Management
  186. [186]

    Vazquez-Piqueras N, Padullés A, Sabé N et al.. “Effect of a multimodal intervention in general and digestive surgery wards on carbapenem use and antimicrobial resistance: protocol for a prospective, quasi-experimental interrupted time-series study.” BMJ open (2026). PMID: 42320964 ↗

    L5OTHERCited in: Empiric and Acute Management
  187. [187]

    Zhao C, Chen C, Lu D et al.. “Antibiotic treatment for 7 days versus 14 days in patients with uncomplicated bloodstream infections: a Systematic review and meta-analysis of randomized controlled trials and trial sequential analysis.” Frontiers in medicine (2025). PMID: 40832108 ↗

    L1SR_MA_RCTCited in: Definitive Therapy, Duration and De-escalation
  188. [188]

    Ray MJ, Strnad LC, Tucker KJ et al.. “Influence of Antibiotic Exposure Intensity on the Risk of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38743579 ↗

    L2OTHERCited in: Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  189. [189]

    Buehrle D, Clancy CJ. “Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34626478 ↗

    L2OTHERCited in: Definitive Therapy, Duration and De-escalation
  190. [190]

    Bhat A, Mansoor A, Fatima M et al.. “Safety and efficacy of fecal microbiota transplantation versus antibiotics for treating clostridioides difficile infection: systematic review and meta-analysis.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 41081988 ↗

    L1SR_OBSCited in: Definitive Therapy, Duration and De-escalation, Complications
  191. [191]

    Ilges D, Ritchie DJ, Krekel T et al.. “Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study.” Open forum infectious diseases (2021). PMID: 34805436 ↗

    L2COHORTCited in: Definitive Therapy, Duration and De-escalation
  192. [192]

    McDonald EG, Butler-Laporte G, Brophy JM et al.. “Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41758514 ↗

    L1RCTCited in: Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  193. [193]

    Keating JA, Xu T, Graham MB et al.. “Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA network open (2025). PMID: 40601321 ↗

    L1RCTCited in: Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  194. [194]

    Bryant JA, Straub TJ, Pardi DS et al.. “Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection.” The Journal of infectious diseases (2025). PMID: 40751372 ↗

    L2TRIAL_NONRANDOMCited in: Definitive Therapy, Duration and De-escalation
  195. [195]

    Taniguchi J, Aso S, Matsui H et al.. “Ampicillin-sulbactam versus third-generation cephalosporins in aspiration Pneumonia: A nationwide retrospective cohort study.” Respiratory medicine (2025). PMID: 40716681 ↗

    L2COHORTCited in: Definitive Therapy, Duration and De-escalation
  196. [196]

    Wolfe TM, Jo J, Pinkham NV et al.. “The impact of ibezapolstat and other Clostridioides difficile infection-relevant antibiotics on the microbiome of humanized mice.” Antimicrobial agents and chemotherapy (2025). PMID: 39998294 ↗

    L5OTHERCited in: Definitive Therapy, Duration and De-escalation
  197. [197]

    Greco Kinney A, Kovacic Scherrer N, Sarkar S et al.. “β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients.” The Journal of antimicrobial chemotherapy (2023). PMID: 37814829 ↗

    L2OTHERCited in: Definitive Therapy, Duration and De-escalation, Complications
  198. [198]

    Britt RS, LaSalvia MT, Padival S et al.. “Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration.” Open forum infectious diseases (2019). PMID: 32128338 ↗

    L2OTHERCited in: Definitive Therapy, Duration and De-escalation, Complications
  199. [199]

    Psarrakis C, Tziolos NR, Matzarakis V et al.. “A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection.” Cell reports. Medicine (2026). PMID: 41483804 ↗

    L1RCTCited in: Definitive Therapy, Duration and De-escalation
  200. [200]

    Fan AE, Alqahtani S, Garnes ND et al.. “Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients: A Multi-Institutional Experience.” Pediatric blood & cancer (2025). PMID: 40879561 ↗

    L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation
  201. [201]

    Straub TJ, Lombardo MJ, Bryant JA et al.. “Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37823484 ↗

    L2RCTCited in: Antimicrobial Resistance and Stewardship
  202. [202]

    Ridgway JP, Robicsek A, Shah N et al.. “A Randomized Controlled Trial of an Electronic Clinical Decision Support Tool for Inpatient Antimicrobial Stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32712674 ↗

    L1RCTCited in: Antimicrobial Resistance and Stewardship
  203. [203]

    Vaughn VM, Gandhi T, Conlon A et al.. “The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30759198 ↗

    L2COHORTCited in: Antimicrobial Resistance and Stewardship
  204. [204]

    Langford BJ, Brown KA, Lau C et al.. “Evaluating Harms Associated With Prolonged Antibiotic Duration of Therapy in Community-Dwelling Older Adults: A Cohort Study Using Instrumental Variable Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39786490 ↗

    L2COHORTCited in: Antimicrobial Resistance and Stewardship
  205. [205]

    Vehreschild MJGT, Ducher A, Louie T et al.. “An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.” The Journal of antimicrobial chemotherapy (2022). PMID: 35016205 ↗

    L1RCTCited in: Antimicrobial Resistance and Stewardship, Complications
  206. [206]

    Seddon MM, Bookstaver PB, Justo JA et al.. “Role of Early De-escalation of Antimicrobial Therapy on Risk of Clostridioides difficile Infection Following Enterobacteriaceae Bloodstream Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30312362 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  207. [207]

    Ong SWX, Patrikar A, Pinto R et al.. “Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial.” Open forum infectious diseases (2026). PMID: 42338985 ↗

    L2TRIAL_NONRANDOMCited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  208. [208]

    Tetteh EK, Obeng H, Atkinson A et al.. “Dissemination of a facilitation strategy to de-implement unnecessary post-operative antibiotics at children's hospitals: The Optimizing Perioperative Antibiotic in Children (OPerAtiC) trial 2.0.” Implementation science : IS (2025). PMID: 41214788 ↗

    L5TRIAL_NONRANDOMCited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  209. [209]

    Wei Q, Wang Y, Rui M et al.. “Health economic evaluations of fecal microbiota transplantation for non-clostridioides difficile related diseases: a systematic review.” Health economics review (2025). PMID: 41400783 ↗

    L2SR_OBSCited in: Antimicrobial Resistance and Stewardship
  210. [210]

    Ventero MP, Valverde-Fredet MD, Merino E et al.. “Antimicrobial Susceptibility of Clostridioides difficile in Spain: Multicenter Retrospective Cohort Study.” Antibiotics (Basel, Switzerland) (2026). PMID: 41750443 ↗

    L2COHORTCited in: Antimicrobial Resistance and Stewardship
  211. [211]

    Park JJ, Jung EJ, Kim JY et al.. “Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing Enterobacterales Bacteremia Receiving Ertapenem versus Other Carbapenems.” Antimicrobial agents and chemotherapy (2022). PMID: 35708330 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  212. [212]

    Dureja C, Rutherford JT, Pavel FB et al.. “In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy.” Antimicrobial agents and chemotherapy (2024). PMID: 38265216 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  213. [213]

    Viana-Cardenas E, Miranti E, Tariq W et al.. “A systematic literature review and bayesian meta-analysis of oral vancomycin primary prophylaxis for Clostridioides difficile infection in stem cell transplant patients.” Antimicrobial stewardship & healthcare epidemiology : ASHE (2025). PMID: 41127168 ↗

    L1SR_OBSCited in: Antimicrobial Resistance and Stewardship
  214. [214]

    Ryazanov V, Vershinina I, Inchagova K et al.. “Fecal microbiota and microbial community transplantation: a review of current research.” Frontiers in microbiology (2026). PMID: 42326403 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  215. [215]

    Hourigan SK, Ahn M, Gibson KM et al.. “Fecal Transplant in Children With Clostridioides difficile Gives Sustained Reduction in Antimicrobial Resistance and Potential Pathogen Burden.” Open forum infectious diseases (2019). PMID: 31660343 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  216. [216]

    Gonzales-Luna AJ, Olaitan AO, Shen WJ et al.. “Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection.” Open forum infectious diseases (2021). PMID: 34381844 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  217. [217]

    Eudy JL, Pallotta AM, Neuner EA et al.. “Antimicrobial Stewardship Practice in the Ambulatory Setting From a National Cohort.” Open forum infectious diseases (2020). PMID: 33269298 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  218. [218]

    Adamowicz E, Kraft CS, Ward T et al.. “Decreased Antimicrobial Resistance Gene Richness Following Fecal Microbiota, Live-jslm (REBYOTA®) Administration: Post Hoc Analysis of PUNCH CD3.” Open forum infectious diseases (2025). PMID: 40672762 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  219. [219]

    Wilk S, Foong KS, Tam R et al.. “Penicillin Allergy Labels and High-risk Antibiotic Prescribing Among Incarcerated Individuals Receiving Antibiotics Across Four US Carceral Systems.” Open forum infectious diseases (2026). PMID: 41889453 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  220. [220]

    Woodworth MH, Hayden MK, Young VB et al.. “The Role of Fecal Microbiota Transplantation in Reducing Intestinal Colonization With Antibiotic-Resistant Organisms: The Current Landscape and Future Directions.” Open forum infectious diseases (2019). PMID: 31363779 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  221. [221]

    Wolf J, Kalocsai K, Fortuny C et al.. “Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31773143 ↗

    L1RCTCited in: Complications
  222. [222]

    Bej TA, Wilson BM, Akpoji UC et al.. “Feasibility of a Low-Intensity Intervention to Influence Antibiotic Prescribing Rates Use in Outpatient Settings: A Cluster Randomized Controlled Clinical Trial.” Open forum infectious diseases (2024). PMID: 39758744 ↗

    L1TRIAL_NONRANDOMCited in: Complications
  223. [223]

    Baral B, Parajuli M, Pinilla J et al.. “Safety and efficacy of oral microbiome therapy for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials.” Scandinavian journal of gastroenterology (2026). PMID: 41543263 ↗

    L1SR_MA_RCTCited in: Complications
  224. [224]

    Omar MA, Katrib M, Shekhar R et al.. “Proton Pump Inhibitor Use for Gastroprotection and Stress Ulcer Prophylaxis Does Not Increase the Risk of Clostridioides difficile Infection or Pneumonia: A Systematic Review and Meta-Analysis of RCTs.” Journal of clinical medicine (2026). PMID: 41976918 ↗

    L1SR_OBSCited in: Complications, Prevention, Infection Control and Special Populations
  225. [225]

    Kao D, Wong K, Lee C et al.. “Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial.” The lancet. Gastroenterology & hepatology (2025). PMID: 40997843 ↗

    L1RCTCited in: Complications
  226. [226]

    Lee C, Feuerstadt P, Louie T et al.. “Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update.” Therapeutic advances in gastroenterology (2025). PMID: 41245385 ↗

    L4TRIAL_NONRANDOMCited in: Complications
  227. [227]

    Tucker EC, Angelica B, Mathias RM et al.. “Outcomes of Fecal Microbiota Transplantation for Clostridioides difficile Infection in South Australia.” Open forum infectious diseases (2025). PMID: 40160347 ↗

    L2OTHERCited in: Complications
  228. [228]

    Tillotson G, Archbald-Pannone L, Johnson S et al.. “Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities.” Open forum infectious diseases (2022). PMID: 36686631 ↗

    L2OTHERCited in: Complications
  229. [229]

    Feuerstadt P, Harvey A, Yoho DS et al.. “Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTATM) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 37256213 ↗

    L2OTHERCited in: Complications, Prognosis and Natural History
  230. [230]

    Liu C, Lan K, Krantz EM et al.. “Improving Appropriate Diagnosis of Clostridioides difficile Infection Through an Enteric Pathogen Order Set With Computerized Clinical Decision Support: An Interrupted Time Series Analysis.” Open forum infectious diseases (2020). PMID: 33094113 ↗

    L2OTHERCited in: Complications
  231. [231]

    Madden GR, Enfield KB, Sifri CD. “Patient Outcomes With Prevented vs Negative Clostridioides difficile Tests Using a Computerized Clinical Decision Support Tool.” Open forum infectious diseases (2020). PMID: 32328506 ↗

    L3OTHERCited in: Complications
  232. [232]

    Cook D, Deane A, Lauzier F et al.. “Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation.” The New England journal of medicine (2024). PMID: 38875111 ↗

    L1RCTCited in: Prognosis and Natural History, Prevention, Infection Control and Special Populations
  233. [233]

    Varma S, Greendyke WG, Li J et al.. “Class-Specific Relationship Between Use of Immunosuppressants and Risk for Community-Acquired Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34156442 ↗

    L2OTHERCited in: Prognosis and Natural History
  234. [234]

    Yu H, Alfred T, Nguyen JL et al.. “Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35686435 ↗

    L2OTHERCited in: Prognosis and Natural History
  235. [235]

    Atamna A, Turjeman A, Drozdinsky G et al.. “Fidaxomicin for Initial Episode of Clostridioides difficile Infection Reduces Recurrence in Immunocompromised Hosts-a Large Retrospective Cohort Study.” Open forum infectious diseases (2025). PMID: 41439186 ↗

    L2COHORTCited in: Prognosis and Natural History, Prevention, Infection Control and Special Populations
  236. [236]

    Chen W, Pan X, Ji J et al.. “Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis.” Frontiers in nutrition (2026). PMID: 41878577 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  237. [237]

    Perez R, Advani SD, North R et al.. “Racial disparities in healthcare-associated infections: a systematic review and meta-analysis.” Infection control and hospital epidemiology (2026). PMID: 42027100 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  238. [238]

    West RM, Smith CJ, Pavitt SH et al.. “'Warning: allergic to penicillin': association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic prescribing and health outcomes.” The Journal of antimicrobial chemotherapy (2019). PMID: 31225607 ↗

    L2OTHERCited in: Prognosis and Natural History
  239. [239]

    Pereira JA, McGeer A, Tomovici A et al.. “The Clinical Burden of Clostridioides difficile in Ontario, Canada.” Open forum infectious diseases (2019). PMID: 32025524 ↗

    L2OTHERCited in: Prognosis and Natural History
  240. [240]

    Johnson SW, Brown SV, Priest DH. “Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31560051 ↗

    L1RCTCited in: Prevention, Infection Control and Special Populations
  241. [241]

    Heil EL, Harris AD, Brown C et al.. “A Multicenter Evaluation of Probiotic Use for the Primary Prevention of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33972996 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  242. [242]

    Yepez Guevara EA, Aitken SL, Olvera AV et al.. “Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32803229 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  243. [243]

    Pakyz AL, Orndahl CM, Johns A et al.. “Impact of the Centers for Medicare and Medicaid Services Sepsis Core Measure on Antibiotic Use.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32827032 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  244. [244]

    Wombwell E, Patterson ME, Bransteitter B et al.. “The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32575126 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  245. [245]

    Nussbaum EZ, Koo S, Kotton CN. “Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38195100 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  246. [246]

    Jones KM, Greene MT, Meddings J et al.. “Impact of a Collaboration-Focused Intervention to Prevent Healthcare-Associated Infections Before and During the COVID-19 Pandemic.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40298392 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  247. [247]

    Berry P, Tariq R, Pardi DS et al.. “Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40759389 ↗

    L2SR_OBSCited in: Prevention, Infection Control and Special Populations
  248. [248]

    Gokhale P, Villa Zapata L. “Opioid use and risk of Clostridioides difficile infection in hospitalized patients: A systematic review and meta-analysis.” American journal of infection control (2025). PMID: 40581048 ↗

    L2SR_OBSCited in: Prevention, Infection Control and Special Populations
  249. [249]

    Maugeri A, Casini B, Esposito E et al.. “Impact of ultraviolet light disinfection on reducing hospital-associated infections: a systematic review in healthcare environments.” The Journal of hospital infection (2025). PMID: 39924116 ↗

    L2SR_OBSCited in: Prevention, Infection Control and Special Populations
  250. [250]

    Keating JA, McKinley L, Dolan K et al.. “Health care worker experiences with a universal gloving intervention to prevent Clostridioides difficile infection: A qualitative study.” American journal of infection control (2025). PMID: 41046913 ↗

    L5RCTCited in: Prevention, Infection Control and Special Populations
  251. [251]

    Banegas M, Villafuerte-Gálvez J, Paredes R et al.. “Preservation of the Innate Immune Response to Clostridioides difficile Infection in Hospitalized Immunocompromised Patients.” Open forum infectious diseases (2023). PMID: 36949876 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  252. [252]

    Alsoubani M, Chow JK, Rodday AM et al.. “Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study.” Open forum infectious diseases (2023). PMID: 38204563 ↗

    L3OTHERCited in: Prevention, Infection Control and Special Populations
  253. [253]

    Alonso CD, Papamichael K, Sprague R et al.. “Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection.” Open forum infectious diseases (2021). PMID: 34258317 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  254. [254]

    Hirsch W, Fischer M, Khoruts A et al.. “Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Study.” Open forum infectious diseases (2025). PMID: 40103733 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations

Revision History

All updates applied to this page

Loading revisions…